149 related articles for article (PubMed ID: 33676848)
1. hTERT, hTR and TERT promoter mutations as markers for urological cancers detection: A systematic review.
Morozov A; Potoldykova N; Chinenov D; Enikeev M; Glukhov A; Shpikina A; Goryacheva E; Taratkin M; Malavaud B; Enikeev D
Urol Oncol; 2021 Aug; 39(8):498.e21-498.e33. PubMed ID: 33676848
[TBL] [Abstract][Full Text] [Related]
2. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer.
Takihana Y; Tsuchida T; Fukasawa M; Araki I; Tanabe N; Takeda M
Int J Urol; 2006 Apr; 13(4):401-8. PubMed ID: 16734859
[TBL] [Abstract][Full Text] [Related]
3. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer.
Weikert S; Krause H; Wolff I; Christoph F; Schrader M; Emrich T; Miller K; Müller M
Int J Cancer; 2005 Nov; 117(2):274-80. PubMed ID: 15900578
[TBL] [Abstract][Full Text] [Related]
4. Effects of combined siRNA-TR and -TERT on telomerase activity and growth of bladder transitional cell cancer BIU-87 cells.
Cheng W; Wei Z; Gao J; Zhang Z; Ge J; Jing K; Xu F; Xie P
J Huazhong Univ Sci Technolog Med Sci; 2010 Jun; 30(3):391-6. PubMed ID: 20556588
[TBL] [Abstract][Full Text] [Related]
5. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
6. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activity and telomerase subunit gene expression levels are not related in prostate cancer: a real-time quantification and in situ hybridization study.
Kamradt J; Drosse C; Kalkbrenner S; Rohde V; Lensch R; Lehmann J; Fixemer T; Bonkhoff H; Stoeckle M; Wullich B
Lab Invest; 2003 May; 83(5):623-33. PubMed ID: 12746472
[TBL] [Abstract][Full Text] [Related]
8. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F
EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840
[TBL] [Abstract][Full Text] [Related]
9. [Development of noninvasive bladder cancer diagnosis on basis of telomerase and it's subunits hTERT and hTR detection].
Glukhov AI; Grigorieva YE; Gordeev SA; Vinarov AZ; Potoldykova NV
Biomed Khim; 2015; 61(1):150-60. PubMed ID: 25762609
[TBL] [Abstract][Full Text] [Related]
10. TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region.
Pakmanesh H; Anvari O; Forey N; Weiderpass E; Malekpourafshar R; Iranpour M; Shahesmaeili A; Ahmadi N; Bazrafshan A; Zendehdel K; Kannengiesser C; Ba I; McKay J; Zvereva M; Hosen MI; Sheikh M; Calvez-Kelm FL
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430798
[TBL] [Abstract][Full Text] [Related]
11. [Effects of combining siRNA-TR and TERT upon telomerase activity and in vitro growth inhibition in transitional cancer of bladder BIU-87 cell line].
Cheng W; Su Y; Ma HQ; Wei ZF; Gao JP; Zhang ZY; Ge JP; Jing KZ; Xu F
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(40):2847-52. PubMed ID: 20137667
[TBL] [Abstract][Full Text] [Related]
12. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
Stögbauer L; Stummer W; Senner V; Brokinkel B
Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
[TBL] [Abstract][Full Text] [Related]
13. Expression of hTERT and hTR in cis reconstitutes and active human telomerase ribonucleoprotein.
Bachand F; Kukolj G; Autexier C
RNA; 2000 May; 6(5):778-84. PubMed ID: 10836798
[TBL] [Abstract][Full Text] [Related]
14. Increased hTR expression during transition from adenoma to carcinoma is not associated with promoter methylation.
Nakamura A; Suda T; Honma T; Takahashi T; Igarashi M; Waguri N; Kawai H; Mita Y; Aoyagi Y
Dig Dis Sci; 2004 Sep; 49(9):1504-12. PubMed ID: 15481329
[TBL] [Abstract][Full Text] [Related]
15. Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.
Marchese PV; Mollica V; Tassinari E; De Biase D; Giunchi F; Marchetti A; Rosellini M; Fiorentino M; Massari F
Expert Rev Mol Diagn; 2022 Nov; 22(11):997-1008. PubMed ID: 36503370
[TBL] [Abstract][Full Text] [Related]
16. Expression-patterns of the RNA component (hTR)and the catalytic subunit (hTERT) of human telomerase in nonneoplastic prostate tissue, prostatic intraepithelial neoplasia, and prostate cancer.
Bettendorf O; Heine B; Kneif S; Eltze E; Semjonow A; Herbst H; Stein H; Böcker W; Poremba C
Prostate; 2003 May; 55(2):99-104. PubMed ID: 12661034
[TBL] [Abstract][Full Text] [Related]
17. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.
Bilsland AE; Merron A; Vassaux G; Keith WN
Cancer Res; 2007 Feb; 67(3):1299-307. PubMed ID: 17283167
[TBL] [Abstract][Full Text] [Related]
18. Detection of telomerase RNA in the plasma of patients with breast cancer, malignant melanoma or thyroid cancer.
Novakovic S; Hocevar M; Zgajnar J; Besic N; Stegel V
Oncol Rep; 2004 Jan; 11(1):245-52. PubMed ID: 14654933
[TBL] [Abstract][Full Text] [Related]
19. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
Roggisch J; Ecke T; Koch S
Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529
[TBL] [Abstract][Full Text] [Related]
20. HTERT promoter methylation and single nucleotide polymorphism (-245 T>C) affect renal cell carcinoma behavior in Serbian population.
Trifunovic J; Basta Jovanovic G; Nikolic N; Carkic J; Marjanovic A; Brankovic M; Radojevic Skodric S; Prvanovic M; Jovanovic A; Dzamic Z; Milasin J
J BUON; 2018; 23(6):1887-1892. PubMed ID: 30610818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
